SETD2 and nonpapillary renal cell carcinoma: These findings collectively implicate SETD2 mutations in promoting metastasis and engendering drug resistance during ccRCC progression, emphasizing the need to better understand molecular pathways altered in SETD2 deficient ccRCC [2].